34% growth, margin pressure; multi-year capacity buildup offset by near-term costs
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 7/10
Grade B
First call post-IPO; no prior guidance to evaluate. Delivered revenue beat expectations (ahead of consolidated entity historical range), but margin pressure suggests execution headwinds on cost absorption.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Tempsens delivered 34% organic revenue growth with strong export momentum (79% YoY) and emerging OEM business backed by 1–2 year order visibility. Long-term trajectory bolstered by ₹500 Cr aggregate peak potential across 5 capacity projects and post-IPO balance sheet strengthening (debt cut 47% to ₹40.7 Cr). Key near-term risk: EBITDA margin compressed 410 bps to 21.2% from employee costs (+41%) and new consolidated entities, delaying profitability recovery.
₹255 Cr
Revenue · +33.7% YoY₹35.7 Cr
Reported PAT · +18.1% YoYCompressing
Margins · vs guidance: UnverifiedDid the claims hold up?
Export revenue more than doubled
MET₹94 Cr from ₹47 Cr implied (37% vs 25% of prior-year total)
EBITDA grew 12%
MET₹54.9 Cr vs ₹49.1 Cr = 11.9% growth
Gross margin 45.7%, in line with FY26 level of 46%
OVERSTATED45.7% reported, but reflects one-time defense order and new lower-margin consolidated entities
Employee cost spike will be absorbed by revenue growth
MISSEmployee cost +41% to ₹42.1 Cr; absorption claim unverified, depends on H2 execution
Earnings quality
What changed since the last call
Export mix shift
UpgradeExports ₹94 Cr (37% of revenue) vs ₹47 Cr (25%) prior year; driven by Tempsens Germany & Polska organic growth + new office in UAE
OEM business emergence
NewFuel cell OEM orders confirmed, 1-yr visibility, expected ~15% of revenue next year; cable harness cross-sell ramping
Balance sheet debt reduction
UpgradeBorrowings ₹40.7 Cr vs ₹77.9 Cr (post-IPO repayment of ₹55 Cr); debt-to-equity 0.06x from 0.15x
Cost inflation headwind
DowngradeEmployee cost +41%, other expenses +37%; margin 21.2% vs 25.2% prior, diluting H1 profitability growth to +18% (vs revenue +34%)
The Q&A
Analysts pressed on margin decline (not fully answered), employee cost absorption timeline (deflected to future quarters), and segment margin breakdown (management refused to disclose). MD stood firm on growth narrative but offered limited specificity on cost normalization, signaling caution on near-term guidance.
Gross margin pressure — Naman Parmar, Niveshaay
PartialNew consolidated entities have lower margin; prior year had one-time defense order with high margin. Overall margin sustainable, will improve with heater dispatches.
Revenue growth split — Abhinav, ICICI Securities
AnsweredTempsens Germany & Polska contributed ~₹25–26 Cr incremental. Organic growth ~25% in temperature sensing. Employees hired for capacity, expected to be absorbed in next half.
Fuel cell OEM ramp — Pratik, Union Mutual Fund
AnsweredExpected ~15% of revenue next year; orders for ~1 year in hand; supplies started in last 2 months. Ramping with sensors & cable harnesses. Margin TBD post-approval.
Capacity utilization & order book — Arvind Arora, GK Capital
AnsweredCapacity utilization ~80%, mostly make-to-order. Traditional order book 3–4 months; OEM visibility 1–2 years. Most output (~95%) is make-to-order today.
Mid-voltage heater TAM — Neel Mehta, ICICI Securities
AnsweredTAM ~US$600–800 million (US$600M–US$800M). Unique to automotive emission control, newer norms; advantage vs incumbents. Joint venture with Victura ramping.
Q2 margin softness & new entities — Gaurav, JM Financial
AnsweredNew consolidated entities (Germany, Poland) have lower blended margin. Prior year FY26 H1 had one-time high-margin defense order. Margin will normalize with heater ramp & standardization.
Temperature sensor integration & IoT — Arnab Bhattacharjee, Individual Investor
AnsweredSensors supply electrical signals to automation systems (PLC/DCS/controller). Tempsens supplies sensors, heaters, or full automation subsystems depending on customer.
OEM ramp & traditional customer mix — Suraj Jain, Individual Investor
AnsweredToday ~80% traditional (heavy industries), ~20% OEM/make-to-order. With new OEMs + standardization, expected to shift to 80% traditional + 20% OEM in 3 years. Complementary, not cannibalistic.
Guidance
FY27 revenue tracking blended growth from 3-yr history
MediumNo formal prior numeric target. H1 delivered +33.7%; consolidations + organic growth sustaining momentum. H2 expected ahead of H1 with product ramps.
Profitability to improve progressively H2 onwards as harnesses, furnace starts, OEM sensors ramp
LowH1 margin compressed to 21.2%; cost absorption timeline vague. Management claims normalization but provides no specific margin targets.
5 projects underway, commissioning Q4 FY27–Q3 FY28, aggregate peak revenue potential ₹500 Cr
MediumH1 capex ₹36.7 Cr (₹26 Cr land, ₹5.9 Cr plant, ₹4.8 Cr construction). Projects: Unit 6 electrical heating (₹200 Cr peak), cable plant 8 (₹60 Cr), contact sensor plant (₹120 Cr), Victura JV facility (₹120 Cr), others.
Risks the call surfaced
Margin recovery execution
HighEBITDA margin fell 410 bps to 21.2% due to ESOP charges (₹1.1 Cr), employee cost inflation (+41%), consolidated entities. Recovery timing vague; if H2 fails to absorb costs, FY27 margin miss structural.
Capacity expansion execution
MediumFive concurrent expansion projects (Q4 FY27–Q3 FY28 timeline) totaling potential ₹500 Cr peak revenue. Execution risk on cost, schedule, and ramp-up. Overspend or delay could impair returns.
OEM business ramp-up
MediumFuel cell OEM business expected ~15% of revenue 'in the next year' (FY28). Orders confirmed for ~1 yr, supplies ramping from Oct 2026, but revenue timing uncertain. If ramp slower, margin recovery delayed.
Consolidated entity margin dilution
MediumTempsens Germany & Polska (consolidated FY27, not in FY26) have lower gross margins, pulling blended margin down 410 bps. Integration costs & margin uplift timeline unclear. Risk of structural margin compression if these entities remain low-margin.
Forex & international exposure
LowExports now 37% of revenue (₹94 Cr), with operations in Germany, Poland, UAE, Mexico. Currency fluctuation or geopolitical disruption (Middle East, Europe) could impact top-line and margins.
Management
Score 7/10. Transparent on margin headwinds (consolidated entities, ESOP costs) and new product roadmap. Evasive on segment margin breakdown (MD declined to disclose). Direct on order book, capacity, and OEM visibility; quantifies where possible (15% OEM target, ₹500 Cr peak potential). First call; no prior guidance to compare. H1 revenue beat expectations (+33.7%), but margin compression (21.2% vs 25.2%) suggests cost absorption slower than expected. Track record on IPO (August 2026) and debt reduction (₹55 Cr repaid) strong; new product ramps unproven.
1 · Q3 FY27 onwards
Furnace supplies begin ramping; ETL/CE approvals enable life science OEM shipments
2 · Q3 FY27 onwards
Specialized cable plant (Unit 8) ramps, targeting ₹60 Cr peak; oil/gas Africa orders executing
3 · Q4 FY27
Five capacity expansion projects begin coming online; first plants commission
Key near-term risk: EBITDA margin compressed 410 bps to 21.2% from employee costs (+41%) and new consolidated entities, delaying profitability recovery.
34% Growth Masks 410 bps Margin Squeeze
Tempsens delivered strong revenue growth, but EBITDA margin compressed sharply due to consolidated entities and cost inflation. The real question: does management absorb these costs in H2, or is the margin miss structural?
₹35.7 Cr
+18.1% YoY
₹54.9 Cr
+11.9% YoY
21.2%
−410 bps from 25.2%
₹255 Cr
+33.7% YoY
Tempsens posted a headline quarter: 34% revenue growth, 79% export surge, and PAT up 18%. On the surface, a solid print. But the earnings tell a different story. EBITDA margin collapsed 410 basis points to 21.2% from 25.2%, dragging profit growth to half the revenue growth rate. The culprits are structural — consolidated acquisition entities with lower margins, an ESOP charge of ₹1.1 Cr, and employee costs up 41% — and management's timeline for absorption remains vague.
The gap: where the margin went
Management cites three headwinds. First, Tempsens Germany and Tempsens Polska (consolidated in FY27, not FY26) carry lower gross margins than the India standalone business. Second, the prior-year H1 benefited from a one-time high-margin defense order that didn't repeat. Third, employee costs spiked 41% to ₹42.1 Cr for capacity hiring. The company claims these will be absorbed as new product lines ramp and utilization improves, but on the call offered no specific margin target or timeline — only that profitability will 'improve progressively' in H2.
Export revenue more than doubled
Supported₹94 Cr vs ₹47 Cr prior year (37% vs 25% of revenue)
EBITDA grew 12%
Supported₹54.9 Cr vs ₹49.1 Cr = 11.9%
Gross margin 45.7%, in line with FY26 46%
Overstated45.7% reported, but prior year included one-time defense order; new consolidated entities lower-margin
Employee cost spike will be absorbed by revenue growth
ContradictedEmployee costs +41% to ₹42.1 Cr; absorption depends on H2 execution, not yet proven
What changed on this call
Three structural shifts emerged:
Export mix shift: Exports now ₹94 Cr (37% of product revenue) vs ₹47 Cr (25%) prior year; +79% YoY driven by Tempsens Germany & Polska organic growth plus new Ajman office for Gulf region
OEM business emergence: Fuel cell OEM orders confirmed with ~1 year visibility; life science furnace approvals (ETL, CE) beginning ramping Oct 2026; mid-voltage heater prototype stage. Target ~15% of revenue 'in the next year'
Balance sheet debt reduction: ₹55 Cr repaid from IPO proceeds (Aug 2026); net debt ₹40.7 Cr vs ₹77.9 Cr prior; debt-to-equity 0.06x from 0.15x
The bull-bear ledger
Strong organic revenue growth (~25% ex-consolidation boost)
Export momentum doubled; now 37% of revenue with 1–2 year OEM visibility vs 3–4 months traditional
₹500 Cr aggregate peak revenue potential from 5 capacity projects (Q4 FY27–Q3 FY28)
Post-IPO balance sheet strength; debt halved; ample cash (OCF ₹50.7 Cr +16.2%)
Niche, defensible products (customized sensors, furnaces, cables); moat from long qualification cycles
EBITDA margin compressed 410 bps (21.2% from 25.2%); recovery timeline vague
Employee cost +41% to ₹42.1 Cr; absorption claim unproven and execution-dependent
PAT growth +18% lags revenue +34%; signals earnings quality deterioration, not momentum
OEM revenue target (15% FY28) early-stage; supplies just ramping; timing uncertain
5 concurrent capex projects at risk of cost overrun or timeline slip (12-month window)
Consolidated entities (Germany, Poland) structurally lower-margin; uplift path unclear
Margin recovery execution
HighEBITDA margin fell 410 bps to 21.2%; management vague on H2 recovery (no specific target or timeline). If cost absorption fails, FY27 margin miss could be structural and repeat into FY28.
Capacity expansion execution
High5 concurrent projects (Q4 FY27–Q3 FY28) targeting ₹500 Cr peak revenue potential. Execution/cost overrun risk high; timeline slip delays profitability uplift.
OEM business materialization
High15% revenue target for FY28 stated vaguely; supplies ramping but bookings/revenue timing unquantified. If OEM ramp slower than guided, margin recovery delayed and full-year growth misses.
Consolidated entity dilution
MediumGermany & Polska lower-margin acquisitions pulling blended margin down 410 bps; integration costs unquantified; uplift path unclear. Risk of structural margin overhang if not resolved.
Forex exposure
LowExports 37% of revenue; ops in Germany, Poland, UAE, Mexico. Currency fluctuation or geopolitical disruption manageable at current rates; hedging strategy not disclosed.
How the street is positioned
The stock is down 12.5% from its all-time high of ₹614.85, currently trading at ₹537.8 — just below its 50-day average (₹539.32) and comfortably above its 20-day (₹520.51). The 52-week range of ₹470.6–₹614.85 places it in the upper half, but the post-IPO pop has faded. RSI at 51.8 (neutral) and volume trending downward suggest cautious positioning. Bulk deal activity over the last 6 months shows balanced buy-sell flows from entities like QE Securities and JunoMoneta, with no insider or promoter-linked red flags near the highs. The market is not panicking — but it's also not rushing back in. The modest drawdown and reduced volume are consistent with a market waiting for margin recovery proof in H2 results, not a fundamental repricing.
The debate
1 · H2 FY27 EBITDA margin trajectory
Does margin recover toward 24–25%, or stay at 21%? This resolves whether cost inflation is temporary or structural. Watch for employee cost stabilization and new product gross margins.
2 · OEM revenue realization in H2 & Q3 FY27
How much fuel cell, furnace, and heater revenue flows in H2? Early ramps matter less than confirmed orders and revenue visibility for FY28. If OEM supply lags guidance, the 15% target for FY28 is at risk.
3 · Q4 FY27 capacity project commissioning
Do the first capex projects (Unit 8 cable plant, furnace expansion) come online on budget and on time? Schedule slip or cost overrun signals execution headwinds across the pipeline.
Tempsens delivered a headline quarter, but the earnings quality is mixed. Strong growth (+34%) is real, but it's being diluted by margin compression (410 bps) from consolidated entities and cost inflation. Management's vagueness on near-term absorption is the red flag.
The stock's 12.5% pullback from its all-time high is rational — the market is waiting for proof that H2 margins recover and the capacity pipeline executes. This is not a panic sell or a screaming buy. It's a stock that needs to demonstrate disciplined cost management and on-time project delivery.
The number to track from here is Q2 FY27 H1 EBITDA margin guidance and realized trajectory in H2 onwards. If margin stabilizes in the 23–25% range and OEM ramps confirm, the stock has room to recover. If margin stays at 21% or compresses further, more downside is likely. Until then, the story is execution-dependent, not a conviction buy.